Sonendo to Present at the 2024 Stifel Jaws & Paws Conference
Get Alerts SONX Hot Sheet
Join SI Premium – FREE
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Sonendo, Inc. (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will present at the upcoming 2024 Stifel Jaws & Paws Conference. Management is scheduled to present on Wednesday, May 29th at 12:00 p.m. Pacific Time/ 3:00 p.m. Eastern Time. An audio webcast of the presentation will be available on the “Investors” section of the company’s website at: investor.sonendo.com.
About Sonendo
Sonendo is a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices.
For more information about Sonendo and the GentleWave System, please visit www.sonendo.com. To find a GentleWave doctor in your area, please visit www.gentlewave.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520877639/en/
Investor Contact:
Greg Chodaczek
Gilmartin Group
[email protected]
Source: Sonendo
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
- Crypto News: Remittix Announces $0.46 Final Price Ahead of Its Market Debut as BNB Price Prediction Targets $1,500
- Bitcoin Price Forecast: September’s Major Options Expiry Passes as Remittix Releases BINANCE500 Rewards
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share